Richter’s syndrome of the central nervous system diagnosed concurrently with chronic lymphocytic leukaemia

A case report and literature review

Liye Xu, MD\textsuperscript{a}, Jin Cheng Song, MD\textsuperscript{b,c}, Xiu Hua Sun, MD\textsuperscript{c}, Zi Fen Gao, PhD\textsuperscript{d}, Li Lv, MD\textsuperscript{e}, Jie Zhu, MD\textsuperscript{f}

Abstract

Rationale: Central nervous system (CNS) infiltration of Richter’s syndrome (RS) is rare and only a few cases were discussed. Of these published cases, either they were accompanied with lymph node involvement or with a history of chronic lymphocytic leukaemia (CLL). To our knowledge, this is the first published case of RS of the brain and meninges diagnosed concurrently with CLL in the absence of any evidence of lymphoma outside of the CNS.

Patient concerns: A 67-year-old female presented with slurred speech, headache, and left-sided hemiparesis. Magnetic resonance imaging of the brain revealed an irregular lesion 30 mm in diameter in the right parietal lobe. The mass was totally removed and pathology revealed diffuse large B-cell lymphoma (DLBCL) of non-germinal center type by Hans’ classification. The patient’s leucocyte count was 12.1 \times 10^9/L (76.3\% lymphocytes), and fluorescence-activated cell sorting (FACS) analysis of blood revealed a clonal B-cell population (36.75\% leukocytes) corresponding to the immunological CLL profile (Matutes score of 5/5). Bone marrow (BM) aspiration and biopsy also indicated CLL. The analysis of immunoglobulin heavy chain gene (IGH) and kappa chain gene (IGK) in the patient’s BM and CNS tissue indicated that the DLBCL of the brain was derived from the CLL clone.

Diagnoses: RS of the CNS diagnosed concurrently with CLL.

Interventions: The patient received intravenous chemotherapy (6.0 g methotrexate) and intrathecal chemotherapy (10 mg methotrexate, 50 mg cytarabine, 5 mg dexamethasone).

Outcomes: The patient returned to our department with left-sided hemiparesis and headache 2 weeks after the chemotherapy. Repeat MRI showed progression of the brain lesion. Her general condition deteriorated significantly with confusion and high fever, and she died within a few days at only 10 weeks after the onset of symptoms.

Lessons: The survival of CNS-RS patients is very poor and is always complicated with multiple and different genetic alterations. Because of chemotherapy insensitivity, a multidisciplinary treatment including surgery and radiotherapy together with novel agents may be an option to improving patient outcomes.

Abbreviations: BM = bone marrow, CLL = chronic lymphocytic leukemia, CNS = central nervous system, CSF = cerebrospinal fluid, DLBCL = diffuse large B-cell lymphoma, FACS = fluorescence-activated cell sorting, IGHV = immunoglobulin heavy chain variable region, MRI = magnetic resonance imaging, PET = positron emission tomography, RS = Richter’s syndrome, RT = Richter’s transformation, SUVmax = maximum standardized uptake value.

Keywords: central nervous system, chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), immunoglobulin heavy chain variable region gene, Richter’s syndrome, Richter’s transformation.
1. Introduction

In 1928, Maurice N. Richter first reported the transformation of B cell chronic lymphocytic leukemia (CLL) into diffuse large B-cell lymphoma (DLBCL), which became known as Richter’s syndrome (RS), or Richter’s transformation (RT). We now know that although DLBCL is the most common type of RS, occurring in approximately 5–10% of CLL patients, other rarer types such as Hodgkin and composite lymphoma also can occur. The reported incidence of RS has varied from 2% to 10% with a median time from CLL diagnosis to RT of 23.0 months. RS is typically characterized by an aggressive presentation, chemotherapy-resistance, and poor survival, with reported median survival times of 8 months and a 5-year survival rate less than 5%. The majority of RS cases occur in lymph nodes, but other primary sites such as the gastrointestinal system, eye, nose, skin, bone, bronchus, and even face have been reported. Central nervous system (CNS) infiltration RS is quite rare. Here we report an unusual case of patient who initially presented with the simultaneous occurrence of CLL in the blood and bone marrow (BM) and DLBCL in the brain and meninges. To our knowledge, this is the first published case of RS of the brain and meninges diagnosed concurrently with CLL in the absence of any evidence of lymphoma outside of the CNS.

2. Case presentation

A 67-year-old female presented with slurred speech, headache, and left-sided hemiparesis in March 2017. Upon admission, she had a white blood cell (WBC) count of 22.2 x 10^9/L and lymphocyte count of 14.5 x 10^9/L, with a normal hemoglobin level and platelet count. Magnetic resonance imaging (MRI) of the brain revealed an irregular lesion with a diameter of 30mm in the right parietal lobe (Fig. 1A). The mass was completely removed via surgical resection and pathological evaluation revealed a diagnosis of DLBCL (Fig. 2), of a non-germinal center type by Hans’ classification. The immune phenotype was CD20 (+), BCL-2 (+, 70%), BCL-6 (+, 40%), CD10 (-), CD21 (-), CD23 (-), CD3 (-), CD5 (+, a few cells), MUM-1 (+), p53 (+, 80%), C-myc (+, 30%), Ki-67 index of 80%, and EBER (-). The patient’s symptoms disappeared after the surgery.

The patient attended to our department in April 2017 for chemotherapy, without night sweats, fever or body weight loss. Peripheral blood examination revealed a hemoglobin level of 120 g/L, a platelet count of 257 x 10^9/L, and a leukocyte count of 12.1 x 10^9/L (76.9% lymphocytes). Fluorescence-activated cell sorting (FACS) analysis of the blood revealed a clonal B-cell population (36.75% leukocytes) co-expressing CD5, CD19, CD23, CD43, CD79b, surface lambda, CD20 (dim), and CD22 corresponding to the immunological profile of CLL (Matutes

Figure 1. Magnetic resonance images of the tumoral lesion in the right parietal lobe before surgery (A); recurrence of the tumor mass at 1 month after surgery (B); and progression of the brain lesion after chemotherapy (C).

Figure 2. Brain tumor histology showed infiltration consistent with DLBCL on hematoxylin-eosin (H&E) staining (40 x 10) (A). Immunocytochemical staining for CD20 within the brain mass was positive (20 x 10) (B). DLBCL = diffuse large B-cell lymphoma.
score of 5/5. Staining results for CD38, CD13, FMC-7, cKappa, and CD10 were negative. BM (BM) aspiration revealed 46.5% mature lymphocytes and 2% prolymphocytes (Fig. 3). FACS analysis of BM also confirmed the diagnosis of CLL. BM biopsy revealed nodular BM infiltration by small lymphocytes, and the immune phenotype was CD20 (+), CD23 (+), CD5 (+), CD3 (−), p53 (+), CyclinD1 (−), and CD10 (−), also consistent with CLL. No lymph node enlargement or hepatosplenomegaly was observed on enhanced computed tomography. Testing for human immunodeficiency virus (HIV) was negative, and the lactase dehydrogenase level was 155 IU/L (normal range: 120–250 IU/L). A patchy, locally enhanced lesion was found in the right parietal lobe of brain on MRI (Fig. 1B). No abnormalities were found on ophthalmological examination. The cerebrospinal fluid (CSF) was turbid, with an elevated protein concentration of 804 mg/dL and normal glucose level of 2.9 mmol/L. Cytological analysis of the CSF revealed many lymphocytes, and some were lymphoma cells. Specifically, we counted 463 lymphocytes, and 200 were B lymphocytes found to express CD20, CD22 and CD19 but not CD5 or CD23 on FACS analysis of the CSF. These FACS results indicated the cells were DLBCL cells. Simultaneous diagnosis of CLL and DLBCL of the CNS was established (RS). However, the relationship between the CNS lesion and peripheral CLL cells was not definite, and thus, we analyzed the expression of immunoglobulin heavy chain gene (IGH) and kappa chain gene (IGK) in the patient’s BM and CNS tissue. The observed amplified segments (monoclonal peaks at 330 bp for IGH and 144 bp for IGK) seemed to be identical and indicated that the DLBCL in the brain was derived from the CLL clone. (Due to copyright issues, we could not present images from the IGH analysis).

The patient received intravenous chemotherapy (6.0 g methotrexate) and intrathecal chemotherapy (10 mg methotrexate, 30 mg cytarabine, 5 mg dexamethasone). Unfortunately, she returned to our department with left-sided hemiparesis and headache after 2 weeks. Repeat MRI showed progression of brain lesion (Fig. 1C). The patient’s condition was too poor for her to receive the planned radiotherapy, and it continued to decline significantly with the development of confusion and high fever. She died within a few days at just 10 weeks after the onset of symptoms.

### Table 1

Reported cases of RS isolated within the CNS.

| Reference       | Age (years) | Gender | Stage of CLL at RS diagnosis | Received chemotherapy | Time from CLL diagnosis to RS (months) | Lesion location | Treatment regimen | Follow-up duration | Alive at last follow-up | Symptoms                  |
|-----------------|-------------|--------|------------------------------|-----------------------|---------------------------------------|----------------|------------------|---------------------|--------------------------|---------------------------|
| O’Neill et al.[16] | 64          | Male   | NA                           | No                    | 36                                    | Left thalamic, brain irradiation       | 24 months       | Yes                | Headache, confusion     |
| 70              | Male        | NA     | Left frontal lobe            | Brain irradiation     | 2 months                             | No                          | 17 months       | NA                 | Language dysfunction,          |
| Mahe et al.[9]  | 64          | Male   | NA                           | Right occipital       | 14 days                              | Chemotherapy, brain irradiation       | NA              | NA                 |right hemiparesis          |
| 70              | Male        | NA     | Right frontal                | Brain irradiation     | 13 months                            | Neurosurgery, chemotherapy, brain irradiation | 14 days         | No                 | Confusion, gait disturbance |
| Penet et al.[17] | 74          | Male   | NA                           | NA                    | 72                                    | Right frontal                        | 12 months       | Yes                | Noise, vomiting, dizziness   |
| Baillis et al.[11] | 78         | Male   | Left thalamic                | Brain irradiation     | 22 days                              | No treatment                         | 12 months       | Yes                | Confusion                 |
| Agard et al.[10] | 61          | Female | Binet A                      | Chemotherapy          | 2 months                             | No                                      |                | NA                 | NA                        |
| Rajic et al.[17] | 58          | Female | Binet B                      | Brain irradiation, rituximab | 3 months                            | Left leg weakness                     | 12 months       | Yes                | Left-sided hemiparesis     |
| Pokak et al.[15] | 60          | Female | Binet A                      | Brain irradiation, rituximab | 14 days                             | Neurosurgery, rituximab, chemotherapy, brain irradiation | 12 months       | Yes                | Nausea, vomiting, dizziness |
| Rousaud et al.[14] | 58         | Male   | Left cerebellum              | Chemotherapy          | 9 months                             | No                                      |                | No                 | Psychotic deficits, left-sided hemiparesis |
| Stapelrodt et al.[14] | 56       | Male   | Left thalamic                | Chemotherapy, brain irradiation | 12 months                           | Right basal ganglia and brainstem      | 10 days         | Gait disturbance, tremors, slurred speech, confusion, visual impairment |
| 71              | Female      | Binet A | Both thalami                 | Rituximab, chemotherapy, brain irradiation | 12 months                           | No                                      |                | NA                 | Double vision, vertigo, gait disturbance |
| Ishida et al.[14] | 66          | Male   | Right putamen                | Rituximab, chemotherapy, brain irradiation | 10 days                             | Right putamen                          | 10 days         | Yes                |Left hemiparesis            |
| Jain et al.[12]  | 67          | Female | Binet A                      | Posterior tons deep, white matter | 10 days                             | Posterior tons deep, white matter      | 10 days         | Gait disturbance, tremors, slurred speech, confusion, visual impairment |
| Schedin et al.[14] | 75          | Male   | No                           | Chemotherapy          | 3 months                             | Pons and medulla                       | 3 months        | No                 | Tachypnoea                 |
| Ghizani et al.[11] | 64          | Male   | No                           | Chemotherapy          | 60                                    | Left occipital                         | 3 months        | No                 | Headache, vomiting, blurry vision |
the present report is unusual and the node involvement or a history of CLL. Thus, the case described in 16 published cases of RS in treated with chemotherapy. [18] However, others have concluded treatment for CLL will increase the risk of RS has remained median survival time of 6.0 months was shorter than the median patients ranged from 10 days to more than 2 years, and the median survival time of 6.0 months was shorter than the median survival time of 8.0 months for RS occurring in other sites. [4] All 16 published cases of RS infiltration of the CNS had either lymph node involvement or a history of CLL. Thus, the case described in the present report is unusual and the first published case to be simultaneously diagnosed with CLL and DLBCL in the brain and meninges without evidence of lymphoma outside of the CNS.

Among the reported cases, the clinical presentation of CNS-RS was headache, hemiparesis, vomiting, and confusion and lacking specific symptoms. Whether the use of chemotherapy as treatment for CLL will increase the risk of RS has remained controversial. Traditional chemotherapy was reported to double the risk of RT to a rate of 1% per annum for those treated with chemotherapy from the rate of 0.5% per annum among those not treated with chemotherapy. [18] However, others have concluded that the evidence for an increased risk of Richter’s transformation in CLL patients treated with chemotherapy in combination with rituximab is inadequate. [19, 20] Multiple factors have been linked to an increased risk of RS in CLL patients, including Rai stages III–IV, lymph node size > 3 cm, deletion of the p53/Rb/p27 genes, mutations of the SAMHD1/XPO1/MED12/NOTCH1/MYC genes, loss of cell cycle inhibitors CDKN1A/CDKN2A/CDKN1B, CD38 expression (CD38 ≥ 30%), stereotyped B-cell receptor, telomere length < 5000 base pairs, absence of del13q14/11q23, overexpression of ZAP70/BCL2/LRP4 genes, decreased expression of MYBL1, immunoglobulin heavy chain variable region (IGHV) homology > 98%, and IGHV gene usage (B-cell receptor subset 8 using IGHV4–39/IGHD6–13/IIGHJ5), trisomy 12, and chromosome 11 abnormalities. [13, 21] Notably, 95% of DLBCL cases resulting from Richter’s transformation display an ABC phenotype, in which staining for CD20 expression is generally positive and that for CD5 and CD23 expression may be dim to negative as in the present case, which is similar to the phenotype of de novo DLBCL. However, molecular profiles including genetic alterations and immunoglobulin gene mutations are found more frequently among patients with RS than those with de novo DLBCL, [22] and these abnormalities may increase the proliferation of CLL cells. In other words, the genetic abnormalities resulting from combinations of multiple, different genetic lesions may promote the development of RS in CLL patients. Importantly, positron emission tomography (PET) can be helpful for identifying RS in CLL patients at high risk. With a maximum standardized uptake value (SUVmax) cut-off of 5.0, PET was shown to detect RT of CLL to DLBCL with a high sensitivity (91%) and high negative predictive value (97%). [23] Papajik et al reported a median SUVmax for suspected or confirmed RT of 16.5. [24] Unfortunately, our patient did not undergo PET-CT scanning for economic reasons. Without the results from such examination, she underwent surgical resection first, which could significantly impact her performance status and which also delayed the administration of chemotherapy and radiotherapy to possibly negative influence her survival.

It is believed that RS cells will express the same surface light chain restriction as its derived CLL clones. [4] In order to definitively determine the clonal relationship of the CNS lesion with the CLL cells in the present case, we examined the sequences of IGH and IGK with the patient’s BM and CNS tissue. Monoclonal peaks at 330 bp for IGH1 and 144 bp for IGK were observed for both the brain DLBCL and BM samples, indicating the gene sequences were identical in the 2 tissue types and that the CLL and DLBCL cells originated from the same B-cell clone. Mao et al found in a study of 23 patients, that RS cells were clonally related to the original CLL (as in our case) in 78% of cases, while the RS cells were clonally unrelated in 22% of cases. [25] The clonally related cells show a higher prevalence of tumor p53 disruption (60.0% versus 23.1% for clonally unrelated cells), [26] which will lead to expression of p53. The expression of p53 by 80% of cells in the brain lesion in the present case indicated that the cancer was aggressive and would be difficult to treat. Hence, it is important to detect p53 expression within lesions as a potential risk factor for poor prognosis among CLL patients. An additional study reported that the clonally related type of RS is characterized by rapid deterioration of performance status, chemotherapy-resistance, immunosuppression, and a poor survival with a median overall survival of 14.2 months versus 62.5 months for the cohort with clonally unrelated RS. [27]

Although rare, RS within the CNS has consistently presented with rapid development, and the optimal treatments remain unknown. Therapeutic regimens established for primary CNS lymphoma have been applied, with chemotherapy combined with rituximab often being used to treat RS. Unfortunately, the results have been generally disappointing due to the chemotherapy-resistance and poor performance status of the patients. [28] Allogeneic stem cell transplantation has been found to improve survival in select patients. [29] Multidisciplinary treatment including surgery and radiotherapy together with stem cell transplantation and novel agents may be an option for chemoresistant RS in patients whose physical condition permits such treatments.

4. Conclusions

To our knowledge, this is the first published case of RS of the brain and meninges that lacked evidence of lymphoma outside of the CNS and was diagnosed concurrent with CLL. Thus, the clinical and pathological descriptions of this case expand the literature related to RS of the CNS. Based on our review of the available but limited literature on RS of the CNS, recognition of risk factors is important for early diagnosis. So far, survival has remained very poor, with RS being insensitive to chemotherapy due to multiple different genetic alterations. Further research is needed to explore the pathogenic mechanism of RS in the CNS and to develop the optimal treatment strategy.

Acknowledgments

We thank Professor Simon for editing and proofreading this manuscript.

Author contributions

LYX and JCS were involved in patient care and data collection and were major contributors in writing the manuscript. XHS and JCS were involved in the study concept and design of the study, JZ performed flow cytometry. ZFG and LL performed the pathological analysis and IGHV analysis, JCS was involved in manuscript editing. All authors read and approved the final manuscript.
References

[1] Molica S. A systematic review on Richter syndrome: what is the published evidence. Leuk Lymphoma 2010;51:415–21.
[2] Rossi D, Cerri M, Capello D, et al. Biological and clinical risk factors of chronic lymphocytic leukemia transformation to Richter syndrome. Br J Haematol 2008;142:202–15.
[3] O’Neill BP, Habermann TM, Banks PM, et al. Primary central nervous system lymphoma as a variant of Richter’s syndrome in two patients with chronic lymphocytic leukemia. Cancer 1989;64:1296–300.
[4] Eyre TA, Schuh A. An update for Richter syndrome – new directions and developments. Br J Haematol 2017;178:508–20.
[5] Omori CE, Omori AE. Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol 2008;142:709–16.
[6] Mahe B, Moreau P, Bonnemain B, et al. Isolated Richter’s syndrome of the brain: two recent cases. Nouv Rev Fr Hematol 1994;36:383–5.
[7] Resende LS, Bacchi CE, Resende LA, et al. Isolated Richter’s syndrome in central nervous system: case report. Arq Neuropsiquiatr 2005;63:530–1.
[8] Baylis KM, Kueck BD, Hanson CA, et al. Richter’s syndrome presenting as primary central nervous system lymphoma. Transformation of an identical clone. Am J Clin Pathol 1990;93:117–23.
[9] Agard G, Hamidou M, Leuzet S, et al. Neuro-meningeal location of Richter syndrome. Rev Med Interne 1999;20:64–7.
[10] Bagic A, Lupu VF, Kessler CM, et al. Isolated Richter’s transformation of the brain. J Neurooncol 2007;83:325–8.
[11] Robak T, Gora-Tybor J, Tybor K, et al. Richter’s syndrome in the brain first manifested as an ischaemic stroke. Leuk Lymphoma 2004;45:1261–7.
[12] Flossand Y, Delabie J, Fossa A, et al. Richter syndrome presenting as a solitary cerebellar tumor during first-line treatment for chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:2007–9.
[13] Stuplich M, Mayer K, Kim Y, et al. Richter syndrome and brain involvement: low-grade lymphoma relapsing as cerebral high-grade lymphoma. Acta Haematol 2012;127:93–5.
[14] Ishida F, Nakazawa H, Takezawa Y, et al. Richter transformation in the brain from chronic lymphocytic leukemia. J Clin Exp Hematop 2013;53:157–60.